---
title: "Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286408124.md"
description: "Canaccord Genuity analyst John Newman has maintained a Buy rating on Allogene Therapeutics (ALLO) with a price target of $14.00. Newman, who focuses on the Healthcare sector, has an average return of 3.8% and a 42.42% success rate on his stock recommendations. The analyst consensus for Allogene Therapeutics is a Strong Buy, with a price target consensus of $8.71."
datetime: "2026-05-14T11:26:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286408124.md)
  - [en](https://longbridge.com/en/news/286408124.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286408124.md)
---

# Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)

In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics, with a price target of $14.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Newman covers the Healthcare sector, focusing on stocks such as Nuvalent, Delcath Systems, and Compass Therapeutics. According to TipRanks, Newman has an average return of 3.8% and a 42.42% success rate on recommended stocks.

Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.71.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [NUVL.US](https://longbridge.com/en/quote/NUVL.US.md)
- [DCTH.US](https://longbridge.com/en/quote/DCTH.US.md)
- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity](https://longbridge.com/en/news/286380061.md)
- [Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing](https://longbridge.com/en/news/286315271.md)
- [Allogene Therapeutics ends China cell therapy deal with Overland](https://longbridge.com/en/news/286317303.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)